Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-17,403
Closed -$2.37M 85
2025
Q4
$2.37M Buy
17,403
+5,490
+46% +$790K 1.84% 13
2025
Q3
$1.76M Buy
11,913
+4,137
+53% +$574K 0.69% 20
2025
Q2
$1.01M Buy
+7,776
New +$942K 0.25% 31
2024
Q4
Sell
-26,319
Closed -$3.55M 69
2024
Q3
$3.55M Buy
26,319
+4,741
+22% +$634K 1.02% 21
2024
Q2
$2.93M Sell
21,578
-11,142
-34% -$1.52M 0.37% 27
2024
Q1
$4.23M Buy
32,720
+3,571
+12% +$431K 1.58% 22
2023
Q4
$3.33K Sell
29,149
-17,325
-37% -$1.73M 0.27% 26
2023
Q3
$4.23K Sell
46,474
-10,896
-19% -$1.12M 0.08% 24
2023
Q2
$6.46K Buy
57,370
+21,362
+59% +$2.26M 1.38% 15
2023
Q1
$3.77M Sell
36,008
-25,222
-41% -$2.63M 1.31% 26
2022
Q4
$6.77M Buy
+61,230
New +$6.42M 2.49% 9

Other funds holding XYL

Trium Capital's XYL Position: Q1 2026 in Review

Trium Capital sold out of Xylem (XYL) in Q1 2026, closing a stake of 17,403 shares — an estimated $2.37M sold.

Trium Capital first reported a position in XYL in Q4 2022 and held it in 11 quarters. The position peaked at $6.77M in Q4 2022. 1,111 funds tracked by Wall St. Rank hold XYL as of Q1 2026.

  • Trium Capital reported no remaining Xylem position as of Q1 2026 after selling out during the quarter.
  • Trium Capital sold 17,403 Xylem shares in Q1 2026, an estimated $2.37M.
  • Trium Capital first reported a position in Xylem in Q4 2022 and held it in 11 quarters.
  • Trium Capital's Xylem position peaked at $6.77M in Q4 2022.
  • 1,111 funds tracked by Wall St. Rank held Xylem as of Q1 2026.

Based on Trium Capital's 13F filing for Q1 2026, filed 16 Apr 2026.